Glenmark launches diabetic drug

Chennai, Oct 26 (IANS) Pharma major Glenmark Pharmaceuticals Limited on Tuesday said it has launched a fixed dose combination drug for Type 2 diabetes.In a statement, Glenmark said the combination contains Remogliflozin (100 mg) + Vildagliptin (50 mg) + Metformin (500/1000 mg) in a fixed dose and must be taken twice daily to improve glycemic control in patients.Glenmark has launched the same under two brand names -- Remo MV and Remozen MV.According to Glenmark, it is the first company in the world to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination and India is the first country to get access to this drug.The company got the regulatory approval in late September 2021.Priced at Rs 16.50 per tablet, a diabetic patient has to take the tablet twice a day and cost per day works out to 53 per cent cheaper than other drugs.According to Alok Malik, Group Vice President & Business Head, India Formulations, the fixed dose combination drug will significantly improve patient compliance and provide glycemic and extra glycemic benefits to patients with uncontrolled type 2 diabetes, in India.
--IANS vj/dpb

(Disclaimer: This post has been auto published from IANS news agency without any modification to the text and has not been reviewed by editor)